Molecular aspects of neuro-oncology

Clinical Neurology and Neurosurgery

Volumn 99, Issue 3, 1997, Pages 184-195

  Santarius, Tomáš ^a,c   Kirsch, Matthias ^a,b   Rossi, Marco L ^c   Black, Peter M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Molecular biology; Nervous system tumors; Pathogenesis

Indexed keywords

GROWTH FACTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BRAIN CANCER; CELL DEATH; CELL PROLIFERATION; MOLECULAR BIOLOGY; NERVOUS SYSTEM TUMOR; PATHOGENESIS; PROGNOSIS; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENOMIC IMPRINTING; GLIOMA; GROWTH SUBSTANCES; HUMANS; MICROSATELLITE REPEATS; MOLECULAR BIOLOGY; MUTAGENESIS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; TELOMERASE;

EID: 0030820215     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-8467(97)00025-5     Document Type: Article

References (141)

1. Cobb MA, Husain M, Andersen BJ, al-Mefty O. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. J Neurosurg 1996;84:85-90.
2. Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal transduction [published erratum appears in Cell 1991 May 31;65(5):following 914]. Cell. 1991;64:281-302.
3. Antoniades HN. PDGF: A multifunctional growth factor. Baillieres Clin Endocrinol Metab 1991;5:595-613.
4. Bowen-Pope DF, Hart CE, Seifert RA. Sera and conditioned media contain different isoforms of platelet-derived growth factor (PDGF) which bind to different classes of PDGF receptor. J Biol Chem 1989;264:2502-8.
5. Matsui T, Heidaran M, Miki T. Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 1989;243:800-4.
6. Hart CE, Forstrom JW, Kelly JD. Two classes of PDGF receptor recognize different isoforms of PDGF. Science 1988;240:1529-31.
7. Harsh GR, Keating MT, Escobedo JA, Williams LT. Platelet derived growth factor (PDGF) autocrine components in human tumor cell lines. J Neuro-Oncol 1990;8:1-12.
8. Hammacher A, Nister M, Westermark B, Heldin CH. A human glioma cell line secretes three structurally and functionally different dimeric forms of platelet-derived growth factor. Euro J Biochem 1988;176:179-86.
9. Nister M, Libermann TA, Betsholtz C. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 1988;48:3910-8.
10. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 1995;60:168-73.
11. Black PM, Carroll R, Glowacka D, Riley K, Dashner K. Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg 1994;81:388-93.
12. Mercola M, Deininger PL, Shamah SM, Porter J, Wang CY, Stiles CD. Dominant-negative mutants of a platelet-derived growth factor gene. Genes Dev 1990;4:2333-41.
13. Shamah SM, Stiles CD, Guha A. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 1993;13:7203-12.
14. Lala P, Angelov L, Provias J, Guha A, Black, PM, Loefler JS, editors. Cancer of the Nervous System. Growth Factors of Nervous System Tumors. Oxford: Blackwell Science, 1997;39:744-72.
15. Goumnerova L, Guha A, Black PM, Schoene WC, Lampson LA, editors. Astrocytomas: Diagnosis, Treatment and Biology. Oncogenes and Growth Factors in Human Astrocytomas. Boston: Blackwell Scientific, 1993;211-27.
16. Weinberg RA. Tumor suppressor genes. Science 1991;254:1138-46.
17. Louis DN, von Deimling A. Hereditary tumor syndromes of the nervous system: Overview and rare syndromes. [Review]. Brain Pathol 1995;5:145-51.
18. Menon AG, Ponder BA, Seizinger BR. The neurofibromatosis genes: From molecular cloning to cellular function. Cancer Cells 1991;3:147-52.
19. Haber DA, Housman DE. Rate-limiting steps: The genetics of pediatric cancers. Cell 1991;64:5-8.
20. Gutmann DH. New insights into the neurofibromatoses. Curr Opin Neurol 1994;7:166-71.
21. Knudson AGJR. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
22. Leon SP, Zhu J, Black PM. Genetic aberrations in human brain tumors. Neurosurgery 1994;34:708-22.
23. Mulligan LM, Mole SE, Levine AJ, Schmidek HH, editors. Strategies for Isolating Genes in Hereditary and Sporadic Tumors. Molecular Genetics of Nervous System Tumors. New York: Wiley-Liss, 1997;15:195-208.
24. Badie B, Drazan KE, Kramar MH, Shaked A, Black KL. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol Res 1995;17:209-16.
25. Feinberg AP. Genomic imprinting and gene activation in cancer. Nat Genet 1993;4:110-3.
26. Antequera F, Boyes J, Bird A. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 1990;62:503-14.
27. Laird PW, Jaenisch R. DNA methylation and cancer. Hum Mol Genet 1994;3:1487-1495.
28. El-Deiry WS, Nelkin BD, Celano P. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci USA 1991;88:3470-3474.
29. Feinberg AP. Alterations in DNA methylation in colorectal polyps and cancer. Prog Clin Biol Res 1988;279:309-17.
30. Cairns P, Mao L, Merlo A. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415-7.
31. Ueki K, Rubio MP, Ramesh V. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 1994;3:1841-5.
32. Kamb A, Gruis NA, Weaver-Feldhaus J. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
33. Merlo A, Herman JG, Mao L. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
34. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991;48:880-8.
35. White E. Tumour biology. p53, guardian of Rb. Nature 1994;371:21-2.
36. Herman JG, Latif F, Weng Y. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-4.
37. Makos M, Nelkin BD, Chazin VR, Cavenee WK, Brodeur GM, Baylin S. DNA hypermethylation is associated with 17p allelic loss in neural tumors. Cancer Res 1993;53:2715-8.
38. Stephens K, Kayes L, Riccardi VM, Rising M, Sybert VP, Pagon RA. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet 1992;88:279-82.
39. Fontaine B, Sanson M, Delattre O. Parental origin of chromosome 22 loss in sporadic and NF2 neuromas. Genomics 1991;10:280-3.
40. Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J, Millasseau P, Vaysseix G, Lathrop M. A second-generation linkage map of the human genome. Nature 1992;359(6398):794-801.
41. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Science 1997;386:623-7.
42. Levinson G, Gutman GA. High frequencies of short frameshifts in poly-CA/TG tandem repeats borne by bacteriophage M13 in Escherichia coli K-12. Nucleic Acids Res 1987;15:5323-38.
43. Strand M, Prolla TA, Liskay RM, Petes TD. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature 1993;365:274-6.
44. Honchel R, Halling KC, Thibodeau SN. Genomic instability in neoplasia. Sem Cell Biol 1995;6:45-52.
45. Aaltonen LA, Peltomaki P, Leach FS. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-6.
46. Louis DN, Gusella JF. A tiger behind many doors: Multiple genetic pathways to malignant glioma. Trends Genet 1995;11:412-5.
47. Rubio MP, Correa KM, Ramesh V. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res 1994;54:45-7.
48. Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-9.
49. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell death and the control of cell survival. Phil Trans R Soc London Series B, Biol Sci 1994;345:265-268.
50. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79:329-39.
51. Vaux DL, Haecker G, Strasser A. An evolutionary perspective on apoptosis. Cell 1994;76:777-9.
52. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
53. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood 1993;82:15-21.
54. Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today 1994;15:7-10.
55. Vaux DL, Weissman IL, Kim SK. Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. Science 1992;258:1955-7.
56. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 1993;143:1543-50.
57. McDonnell TJ, Troncoso P, Brisbay SM. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
58. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994;9:3367-70.
59. Lotem J, Sachs L. Regulation by bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differentiation 1993;4:41-7.
60. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
61. Ohmori T, Podack ER, Nishio K. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993;192:30-6.
62. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
63. McCarthy SA, Symonds HS, Van Dyke T. Regulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53. Proc Natl Acad Sci USA 1994;91:3979-83.
64. Lowe SW, Bodis S, McClatchey A. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
65. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 1993;82:1092-6.
66. Nagata S, Golstein P. The fas death factor. Science 1995;267:1449-1456.
67. Oehm A, Behrmann I, Falk W. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Bio Chem 1992;267:10709-15.
68. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H. Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 1995;55:5528-30.
69. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994;94:954-64.
70. Greider CW. Telomeres. Curr Opin Cell Biol 1991;3:444-51.
71. Greider CW. Telomeres, telomerase and senescence. Bioessays 1990;12:363-9.
72. Blackburn EH. Structure and function of telomeres. Nature 1991;350:569-73.
73. Goldstein S. Replicative senescence: The human fibroblast comes of age. Science 1990;249:1129-33.
74. Hiyama K, Ishioka S, Shirotani Y. Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb. Oncogene 1995;10:937-44.
75. Broccoli D, Cooke H. Aging, healing and the metabolism of telomeres. Am J Hum Genet 1993;52:657-60.
76. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990;346:866-8.
77. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication problem and cell aging. J Mol Biol 1992;225:951-60.
78. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 1994;91:2900-4.
79. Hiyama E, Hiyama K., Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249-55.
80. Buckingham M. Making muscle in mammals. Trends Genet 1992;8:144-8.
81. Lyon MF. Epigenetic inheritance in mammals. Trends Genet 1993;9:123-8.
82. Russell DS, Rubinstein LJ, Russell DS, Rubinstein LJ, editors. Medulloblastomas. Pathology of Tumors of the Nervous System. 5th ed. Baltimore: Williams and Wilkins, 1989:251-279.
83. Bailey P, Cushing H. Medulloblastoma cerebelli: A common type of midcerebellar tumor of childhood. Arch Neurol Psychiatry 1925;14192:224.
84. Valtz NL, Hayes TE, Norregaard T, Liu SM, McKay RD. An embryonic origin for medulloblastoma. New Biologist 1991;3:364-71.
85. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992;255:1707-10.
86. Hayes TE, McKay RD, Levine AJ, Schmidek HH, editors. Molecular Genetics of Nervous System Tumors. Differentiation of Cell Types in the Central Nervous System. New York: Wiley-Liss, 1990;2:37-48.
87. Jacoby LB, Levine AJ, Schmidek HH, editors. Molecular Genetics of Nervous System Tumors. Clonal Origin of Nervous System Tumors. New York: Wiley-Liss, 1993;16:209-215.
88. Morse RP, Darras BT, Ye Z, Wu JK. Clonal analysis of human astrocytomas. J Neuro-Oncol 1994;21:151-7.
89. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
90. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992;355:846-7.
91. Zhu J, Frosch MP, Busque L. Analysis of meningiomas by methylation-and transcription-based clonality assays. Cancer Res 1995;55:3865-72.
92. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumors of the Central Nervous System. 2nd edn. New York: Springer-Verlag, 1993.
93. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19-26.
94. Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427-36.
95. von Deimling A, Eibl RH, Ohgaki H. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992;52:2987-90.
96. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992;52:674-9.
97. Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992;52:1427-33.
98. Louis DN, von Deimling A, Chung RY. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 1993;52:31-8.
99. Chung RY, Seizinger BR. Tumor suppressor genes and cancer of the human nervous system. Cancer Invest 1991;9:429-37.
100. Venter DJ, Bevan KL, Ludwig RL. Retinoblastoma gene deletions in human glioblastomas. Oncogene 1991;6:445-8.
101. Henson JW, Schnitker BL, Correa KM. The retinoblastoma gene is involved in malignant progression of astrocytomas. Annals Neurol 1994;36:714-21.
102. Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M. p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer 1993;55:982-7.
103. Fults D, Pedone CA, Thomas GA. White R. Allelotype of human malignant astrocytoma. Cancer Res 1990;50:5784-9.
104. James CD, Carlbom E, Dumanski JP. Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988;48:5546-51.
105. von Deimling A, Louis DN, von Ammon K. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992;77:295-301.
106. Venter DJ, Thomas DG. Multiple sequential molecular abnormalities in the evolution of human gliomas. Br J Cancer 1991;63:753-7.
107. Leenstra S, Bijlsma EK, Troost D, Oosting J, Westerveld A, Bosch DA. Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. Br J Cancer 1994;70:684-9.
108. Folkman J. Tumor angiogenesis: Therapeutic implications. New Eng J Med 1971;285:1182-6.
109. Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972;136:261-76.
110. Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976;36:2807-12.
111. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
112. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. New Eng J Med 1995;333:1757-63.
113. Weidner N. Angiogenesis in breast cancer. Cancer Treatment Res 1996;83:265-301.
114. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 1994;144:1188-94.
115. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treatment 1995;36:169-80.
116. Li VW, Folkerth RD, Watanabe H, Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994;344:82-6.
117. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-72.
118. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 1994;34:869-75.
119. Takamiya Y, Friedlander RM, Brem H, Malick A. Martuza RL. Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J Neurosurg 1993;78:470-6.
120. Lee JK, Choi B, Sobel RA, Chiocca EA, Martuza RL. Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. J Neurosurg 1990;73:429-35.
121. Weingart JD, Sipos EP, Brem H. The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 1995;82:635-40.
122. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
123. O'Reilly MS, Holmgren L, Shing Y. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
124. Ohgaki H, Eibl RH, Schwab M. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 1993;8:74-80.
125. Seizinger BR, Rouleau GA, Ozelius LJ. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell 1987;49:589-94.
126. Barker D, Wright E, Nguyen K. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 1987;236:1100-2.
127. Fountain JW, Wallace MR, Bruce MA. Physical mapping of a translocation breakpoint in neurofibromatosis. Science 1989;244:1085-7.
128. Cawthon RM, Weiss R, Xu GF. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990;62:193-201.
129. Viskochil D, Buchberg AM, Xu G. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990;62:187-92.
130. Wallace MR, Marchuk DA, Andersen LB. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients. Science 1990;249:181-6.
131. Platten M, Giordano MJ, Dirven CM, Gutmann DH, Louis DN. Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol 1996;149:621-7.
132. Rouleau GA, Wertelecki W, Haines JL. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 1987;329:246-8.
133. Fontaine B, Hanson MP, VonSattel JP, Martuza RL, Gusella JF. Loss of chromosome 22 alleles in human sporadic spinal schwannomas. Annals Neurol 1991;29:183-6.
134. Rouleau GA, Merel P, Lutchman M. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-21.
135. Jacoby LB, MacCollin M, Louis DM. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 1994;3:413-9.
136. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet 1994;3:347-50.
137. Seizinger BR, Rouleau GA, Ozelius LJ. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332:268-9.
138. Latif F, Tory K, Gnarra J. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
139. Kanno H, Kondo K, Ito S. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994;54:4845-7.
140. Nishikawa R, Furnari FB, Lin H. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res 1995;55:1941-5.
141. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995;267:249-52.